Shenzhen Hornetcorn Bio-technology CompanyLTD
Autologous NK cell therapy(Shenzhen Hornetcorn Bio-technology Company, LTD)은 NK Cell Mediated Immunity 표적 세포·유전자 치료로, NK Cell Mediated Immunity; Endometriosis 영역에서 개발·상용화 중입니다. 작용기전: targeting both CAR antigen. Phase 1 안전성·PK 탐색 단계입니다. PFS: 2. 차별점: novel treatment to establish its efficacy in HCC.
NK Cell Mediated Immunity
NK Cell Mediated Immunity; Endometriosis
Active
NK cell therapy in combination with hepatic arterial infusion chemo
retroviral therapy (ART) and evade immune clearance
humanized preclinical models, and accessibility strategies
novel treatment to establish its efficacy in HCC
targeting both CAR antigen
NK cells, their antibody-dependent cellular cytotoxicity
biomarker of disease biology
resistance to killing by other cell types such as NK and CD8+ T cells
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Shenzhen Hornetcorn Bio-technology CompanyLTD
Autologous NK cell therapy(Shenzhen Hornetcorn Bio-technology Company, LTD)은 NK Cell Mediated Immunity 표적 세포·유전자 치료로, NK Cell Mediated Immunity; Endometriosis 영역에서 개발·상용화 중입니다. 작용기전: targeting both CAR antigen. Phase 1 안전성·PK 탐색 단계입니다. PFS: 2. 차별점: novel treatment to establish its efficacy in HCC.
NK Cell Mediated Immunity
NK Cell Mediated Immunity; Endometriosis
Active
NK cell therapy in combination with hepatic arterial infusion chemo
retroviral therapy (ART) and evade immune clearance
humanized preclinical models, and accessibility strategies
novel treatment to establish its efficacy in HCC
targeting both CAR antigen
NK cells, their antibody-dependent cellular cytotoxicity
biomarker of disease biology
resistance to killing by other cell types such as NK and CD8+ T cells
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.